SIM-0237
- Generic Name
- SIM-0237
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC
Phase 1
Recruiting
- Conditions
- Non-Muscle-Invasive Bladder Cancer (NMIBC)
- Interventions
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 152
- Registration Number
- NCT06186414
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang, China
🇨🇳Renmin Hospital of Wuhan University, Wuhan, Hubei, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Locally Advanced Unresectable or Metastatic Solid Tumor
- Interventions
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 192
- Registration Number
- NCT05781360
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸NYU Langone, New York, New York, United States
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath